Patents Examined by Marsha Tsay
  • Patent number: 11884705
    Abstract: Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin ? chain binding activity.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 30, 2024
    Assignees: JSR CORPORATION, JSR Life Sciences Corporation, JSR Life Sciences, LLC, JSR Micro N.V.
    Inventors: Jun-ichi Yasuoka, Kiichi Yoshimura, Tomoaki Haga
  • Patent number: 11867685
    Abstract: The invention relates to the identification of OR5A2 as an Olfactory Receptor that binds natural musk and synthetic musks. The invention encompasses the use of the interaction of OR5A2 polypeptides and nitromusk, polycyclic musk, macrocyclic musk and alicyclic musks as the basis of screening assays for agents that specifically modulate the activity of the OR of the invention.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: January 9, 2024
    Assignee: CHEMCOM S.A.
    Inventors: Sandra Huysseune, Alex Veithen, Yannick Quesnel
  • Patent number: 11866714
    Abstract: A promoter operably linked to a gene encoding a protein is disclosed. The promoter drives expression of the protein in a yeast cell in the absence of methanol. Also disclosed are vectors, host cells and expression systems that include the promoter, as well as methods of using the promoter to express proteins in yeast.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: January 9, 2024
    Assignee: BASF SE
    Inventors: Xuqiu Tan, Ruorong Cai, Jingping Zhong, Melissa Ann Scranton, Michael Speer
  • Patent number: 11859190
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 2, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 11851666
    Abstract: The present invention belongs to the field of biotechnology, specifically to the field of recombinant protein expression. The present invention focuses on two problems commonly encountered during recombinant protein expression, low quantity of protein expression and genetic instability of cell lines used for recombinant protein expression. The basic principle of the present invention is to introduce several expression cassettes into a cell which expression cassettes all code for the same mature recombinant protein of interest, but which expression cassettes have different nucleotide sequences. Expression cassette means a polynucleotide sequence which comprises at least a promoter sequence, a start codon, a polynucleotide sequence coding for a protein which is intended to be recombinant expressed (POI), a stop codon and a terminator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: December 26, 2023
    Inventors: Clemens Achmüller, Norbert Lamping, Matjaz Vogelsang
  • Patent number: 11845780
    Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 19, 2023
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Mark Bruce, James Anthony Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace
  • Patent number: 11834479
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: December 5, 2023
    Inventors: Floyd E. Romesberg, Yorke Zhang
  • Patent number: 11834652
    Abstract: The present invention includes compositions and methods for promoting scarless genome editing in a cell. In one aspect, methods of the invention utilize the CRISPR/Cas9 system to introduce a cut site into a genomic location to be edited. In another aspect, methods of the invention integrate an edited sequence into that genomic location in a scarless manner.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: December 5, 2023
    Inventors: Murat Acar, Gregory Elison
  • Patent number: 11820987
    Abstract: This invention relates to compositions and methods for the production of Type III polyketides using genetically modified oleaginous yeast strains, for example, Yarrowia lipolytica.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 21, 2023
    Inventors: Hal Alper, Kelly Markham, Claire Palmer
  • Patent number: 11807856
    Abstract: A recombinant Pichia pastoris strain which is genetically modified for highly expressing pediocin PA-1 and secreted into a medium so that the pediocin PA-1 is easily collected and purified from the culture medium. The obtained pediocin PA-1 has specific antimicrobial activities against Listeria monocytogenes ATCC 13932 and several other bacteria strains.
    Type: Grant
    Filed: January 1, 2019
    Date of Patent: November 7, 2023
    Inventors: Phuong Thao Thi Dang, My Trinh Thi Nguyen, Nghia Hieu Nguyen, Thuoc Linh Tran, Anh Thu Pham Nguyen
  • Patent number: 11795194
    Abstract: A method for purifying phycocyanin from a phycocyanin-containing solution is provided. The method comprises a first step of partially purifying the solution by aqueous two-phase separation (ATPS) and a second step of purifying the phycocyanin by ammonium sulfate precipitation. The purified phycocyanin product can in some cases be of a sufficiently pure grade to be used as a food or cosmetic pigment.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 24, 2023
    Assignee: University of Cape Town
    Inventors: Susan Thérèse Largier Harrison, Matthew Armstrong Burke, Robert William McClelland Pott, Marijke Antonia Fagan-Endres
  • Patent number: 11787846
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 17, 2023
    Inventors: Walter J. Storkus, Michael S. Kinch
  • Patent number: 11774461
    Abstract: The present invention pertains to the field of coagulation diagnostics and relates to a prothrombin time reagent on the basis of recombinant or native tissue factor protein and phospholipids, which reagent can be stabilized by the addition of an iron chelator from the groups of siderophores and 3,5-diphenyl-1,2,4-triazoles.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: October 3, 2023
    Assignee: Siemens Healthcare Diagnostics Products GMBH
    Inventors: Sabine Pilgrim, Thomas Wissel, Norbert Zander
  • Patent number: 11753663
    Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. Also provided herein are methods for using such an organism to produce adipate, 6-aminocaproate, hexamethylenediamine or caprolactam.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: September 12, 2023
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
  • Patent number: 11746348
    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: September 5, 2023
    Assignee: GENTIUM S.R.L.
    Inventors: Terenzio Ignoni, Vijay Kumar, Khalid Islam
  • Patent number: 11718687
    Abstract: A bioelectronic device for regulating stem cell differentiation, a method for differentiating stem cells using the same, and a method for manufacturing the bioelectronic device. According to the present invention, it is possible to effectively control the differentiation of stem cells at a single-cell level, and to simultaneously perform a free radical inhibition function.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: August 8, 2023
    Inventors: Jeong Woo Choi, Sang Uk Kim, Jin Ho Yoon, Mohsen Mohammadniaei
  • Patent number: 11708570
    Abstract: Factor IX/IXa variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 25, 2023
    Inventors: Valder R. Arruda, Rodney M. Camire, Benjamin Samelson-Jones
  • Patent number: 11639504
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 2, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 11633454
    Abstract: The disclosure provides compositions and methods of treating a metabolic disease, such as, e.g., diabetes and hyperlipidemia, in a subject, by administering to the subject a therapeutically effective amount of a polypeptide derived from hepatitis B virus or a pharmaceutical composition comprising the polypeptide.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 25, 2023
    Inventor: Hongli Liu
  • Patent number: 11634736
    Abstract: Methods and materials for the production of compounds involved in the TCA cycle, and/or derivatives thereof and/or compounds related thereto are provided. Also provided are products produced in accordance with these methods and materials.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: April 25, 2023
    Inventors: Emilie Sophie Fritsch, Alexander Brett Foster